JP2014532074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532074A5 JP2014532074A5 JP2014536177A JP2014536177A JP2014532074A5 JP 2014532074 A5 JP2014532074 A5 JP 2014532074A5 JP 2014536177 A JP2014536177 A JP 2014536177A JP 2014536177 A JP2014536177 A JP 2014536177A JP 2014532074 A5 JP2014532074 A5 JP 2014532074A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- cells
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical class 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims 23
- 102000040430 polynucleotide Human genes 0.000 claims 15
- 108091033319 polynucleotide Proteins 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 11
- 102000000704 Interleukin-7 Human genes 0.000 claims 4
- 108010002586 Interleukin-7 Proteins 0.000 claims 4
- 229940100994 interleukin-7 Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000003042 antagnostic effect Effects 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 238000010367 cloning Methods 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 102000052622 human IL7 Human genes 0.000 claims 2
- 102000049284 human IL7R Human genes 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000009795 derivation Methods 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306353.1 | 2011-10-19 | ||
| EP11306353.1A EP2583980A1 (en) | 2011-10-19 | 2011-10-19 | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| PCT/EP2012/069670 WO2013056984A1 (en) | 2011-10-19 | 2012-10-04 | Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017106295A Division JP6621778B2 (ja) | 2011-10-19 | 2017-05-30 | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014532074A JP2014532074A (ja) | 2014-12-04 |
| JP2014532074A5 true JP2014532074A5 (OSRAM) | 2016-05-19 |
Family
ID=47018987
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536177A Pending JP2014532074A (ja) | 2011-10-19 | 2012-10-04 | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 |
| JP2017106295A Active JP6621778B2 (ja) | 2011-10-19 | 2017-05-30 | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017106295A Active JP6621778B2 (ja) | 2011-10-19 | 2017-05-30 | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9447182B2 (OSRAM) |
| EP (3) | EP2583980A1 (OSRAM) |
| JP (2) | JP2014532074A (OSRAM) |
| ES (1) | ES2854708T3 (OSRAM) |
| WO (1) | WO2013056984A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2482342B1 (es) * | 2012-12-27 | 2015-07-02 | Consejo Superior De Investigaciones Científicas (Csic) | TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| EP3207061A1 (en) | 2014-10-18 | 2017-08-23 | Pfizer Inc | Anti-il-7r antibody compositions |
| WO2016156466A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| JP2018511346A (ja) | 2015-03-31 | 2018-04-26 | ブイエイチスクエアード リミテッド | ポリペプチド |
| WO2017051273A1 (en) * | 2015-09-22 | 2017-03-30 | Pfizer Inc. | Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| US10392441B2 (en) | 2015-10-07 | 2019-08-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
| ES2737307T3 (es) * | 2016-02-29 | 2020-01-13 | Ose Immunotherapeutics | Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer |
| RS61808B1 (sr) | 2016-12-09 | 2021-06-30 | Ose Immunotherapeutics | Antitela i polipeptidi usmereni protiv cd127 |
| JP7239181B2 (ja) | 2017-04-04 | 2023-03-14 | ロマ リンダ ユニヴァーシティ | 癌治療のための生物製剤 |
| US12258577B2 (en) | 2017-08-29 | 2025-03-25 | Ose Immunotherapeutics | Method effector cells using anti-CD127 antibodies for applications in cell therapy |
| WO2020154293A1 (en) * | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
| JP7680377B2 (ja) | 2019-06-21 | 2025-05-20 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| JP7702363B2 (ja) | 2019-06-21 | 2025-07-03 | ソリッソ ファーマシューティカルズ，インク． | 組成物 |
| CN114466864B (zh) | 2019-06-21 | 2024-12-27 | 索瑞索制药公司 | 多肽 |
| JP2025518164A (ja) | 2022-05-30 | 2025-06-12 | オセ イムノセラピューティクス | Ｉｌ７ｒモジュレーター活性のバイオマーカー |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025089399A1 (ja) * | 2023-10-26 | 2025-05-01 | 国立研究開発法人国立がん研究センター | インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ） |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3431585A1 (en) * | 2006-05-31 | 2019-01-23 | The Regents of The University of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| SI3187506T1 (sl) * | 2007-05-21 | 2019-08-30 | Alderbio Holdings Llc | Protitelesa proti IL-6 in njihova uporaba |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| WO2010085643A1 (en) * | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| US8815242B2 (en) * | 2009-05-27 | 2014-08-26 | Synageva Biopharma Corp. | Avian derived antibodies |
| UY33202A (es) * | 2010-01-28 | 2011-08-31 | Glaxo Group Ltd | Proteínas de unión a cd127 |
| TWI552760B (zh) | 2010-02-24 | 2016-10-11 | 雷那特神經科學股份有限公司 | 拮抗劑抗－ｉｌ－７受體抗體及方法 |
-
2011
- 2011-10-19 EP EP11306353.1A patent/EP2583980A1/en not_active Withdrawn
-
2012
- 2012-10-04 JP JP2014536177A patent/JP2014532074A/ja active Pending
- 2012-10-04 US US14/352,992 patent/US9447182B2/en active Active
- 2012-10-04 WO PCT/EP2012/069670 patent/WO2013056984A1/en not_active Ceased
- 2012-10-04 EP EP12772749.3A patent/EP2768860A1/en not_active Withdrawn
- 2012-10-04 EP EP17200006.9A patent/EP3299392B1/en active Active
- 2012-10-04 ES ES17200006T patent/ES2854708T3/es active Active
-
2017
- 2017-05-30 JP JP2017106295A patent/JP6621778B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532074A5 (OSRAM) | ||
| JP6681327B2 (ja) | 抗ｐｄ−１抗体およびその応用 | |
| JP6621778B2 (ja) | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 | |
| US12448423B2 (en) | Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains | |
| CA2932966C (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof | |
| AU2018228719B2 (en) | Tandem diabody for CD16A-directed NK-cell engagement | |
| JP2020529832A (ja) | ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質 | |
| JP2021521784A (ja) | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 | |
| TW202126694A (zh) | 標靶cd3的抗體、雙特異性抗體及其用途 | |
| TW202012441A (zh) | Nk細胞接合抗體融合構築體 | |
| JP7355977B2 (ja) | Ｃｄ２４に結合する抗体、その調製および使用 | |
| CN112119093A (zh) | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 | |
| AU2021364387A9 (en) | Fusions with cd8 antigen binding molecules for modulating immune cell function | |
| CN106986939B (zh) | 抗pd-1和tem-8双特异性抗体及其应用 | |
| CN105473617A (zh) | 针对人csf-1r的抗体和针对人pd-l1的抗体的组合疗法 | |
| JP2013515508A (ja) | Ｒｏｎ結合構築体およびその使用方法 | |
| AU2016369307A1 (en) | Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F | |
| CN110790837A (zh) | 抗btla抗体 | |
| IL300930A (en) | Methods and compositions for the treatment of autoimmune diseases and cancer | |
| JP2024539749A (ja) | 新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用 | |
| CN117355540A (zh) | 抗cd137抗体和使用方法 | |
| CN118055946A (zh) | 新型多特异性分子 | |
| CN114829398B (zh) | 对人il-13具有结合特异性的抗体 | |
| WO2019072274A1 (zh) | 一种激动型4-1bb单克隆抗体 | |
| WO2025209593A1 (zh) | 一种多特异性抗体t细胞衔接器 |